Icelandic
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
Bls 1 frá 60 niðurstöður
Insulin resistance and endogenous digoxin-like factor in obese hypertensive patients with glucose intolerance.
Aðeins skráðir notendur geta þýtt greinar
Skráðu þig / skráðu þig
Hypertensive obese subjects with glucose intolerance have hyperinsulinaemia, insulin resistance and intracellular cation imbalance resulting in increased sodium content. The aim of our study was to assess in these patients plasma levels of endogenous digoxin-like factor (EDLF), an inhibitor of the
Digoxin disposition in obesity: clinical pharmacokinetic investigation.
Aðeins skráðir notendur geta þýtt greinar
Skráðu þig / skráðu þig
Digoxin pharmacokinetics were studied in 16 obese (mean +/- SD weight, 100.2 +/- 36.8 kg) and 13 control (64.6 +/- 10.5 kg) subjects. All subjects had normal renal function and no other coexisting disease. After administration of 0.75 mg digoxin by intravenous infusion, multiple plasma samples
Decrease of intracranial pressure and weight with digoxin in obesity.
Aðeins skráðir notendur geta þýtt greinar
Skráðu þig / skráðu þig
Fourteen obese patients (body mass index = 34-47 kg/m2; mean = 40 kg/m2) with lumbar cerebrospinal fluid pressure (Pcsf) above 20 cm water in 10 of the 14 patients were treated with digoxin with a serum concentration of at least 1.0 nmol/L (0.8 ng/ml) for 6 months. Pcsf decreased significantly
The effect of maternal obesity on the expression and functionality of placental P-glycoprotein: Implications in the individualized transplacental digoxin treatment for fetal heart failure.
Aðeins skráðir notendur geta þýtt greinar
Skráðu þig / skráðu þig
BACKGROUND
Placental P-glycoprotein (P-gp) plays a significant role in controlling digoxin transplacental rate. Investigations on P-gp regulation in placenta of women with different pregnant pathology are of great significance to the individualized transplacental digoxin treatment for fetal heart
Corrigendum to "The effect of maternal obesity on the expression and functionality of placental P-glycoprotein: Implications in the individualized transplacental digoxin treatment for fetal heart failure" [Placenta 36 (2015) 1138-1147].
Aðeins skráðir notendur geta þýtt greinar
Skráðu þig / skráðu þig
Digoxin metabolism in obesity.
Aðeins skráðir notendur geta þýtt greinar
Skráðu þig / skráðu þig
Digoxin maintenance dosage in obesity.
Aðeins skráðir notendur geta þýtt greinar
Skráðu þig / skráðu þig
[Characteristics of obese patients in intensive care].
Aðeins skráðir notendur geta þýtt greinar
Skráðu þig / skráðu þig
BACKGROUND
The frequency of overweight, together with the associated increase in morbidity--in particular coronary heart disease--means that such patients often require intensive care.
UNASSIGNED
The particular features of intensive care of obese patients are the increased risk of aspiration
Digoxin-like immunoreactivity may contribute to hyperinsulinemia-associated hypertension in patients with glucose intolerance.
Aðeins skráðir notendur geta þýtt greinar
Skráðu þig / skráðu þig
The role of endogenous digitalis-like factors in the pathogenesis of the hypertension associated with impaired glucose tolerance was investigated by measuring plasma digoxin-like immunoreactivity (DLI). Mean blood pressure correlated significantly with the obesity index, serum insulin-like
Digoxin use and following risk of psoriasis: A population-based cohort study in Taiwan.
Aðeins skráðir notendur geta þýtt greinar
Skráðu þig / skráðu þig
This study examined the association between digoxin use and subsequent psoriasis risk using a population-based database in Taiwan. This cohort study enrolled 15 545 digoxin users and 15 545 propensity score-matched non-users from the Taiwan National Health Insurance Research Database. Each patient
The effect of jejunoileal bypass on the pharmacokinetics of digoxin in man.
Aðeins skráðir notendur geta þýtt greinar
Skráðu þig / skráðu þig
Seven subjects who underwent jejunoileal bypass surgery for massive obesity participated in a study to examine the relative bioavailability of digoxin before and one to two months after surgery. They were given a loading dose of 1 mg digoxin in divided oral doses followed by oral maintenance doses
Pharmacokinetics of drugs in obesity.
Aðeins skráðir notendur geta þýtt greinar
Skráðu þig / skráðu þig
Pharmacokinetic data in obesity are only available for a limited number of drugs. The rate or extent of drug absorption is not known to be altered by obesity which is not complicated by other medical disease. In contrast, drug distribution is in some instances significantly altered in obesity.
[Radioimmunologic determination of serum digoxin. Methodological and 1st clinical experiences].
Aðeins skráðir notendur geta þýtt greinar
Skráðu þig / skráðu þig
The tested quality signs of the digoxin-RIA (Medica) correspond to other RIA-test methods. The digoxin-RIA (Medica) is, therefore, well suited for clinical examinations. In the dilanacin- (digoxin-) long-term therapy with the maintenance dose of 0.5 mg digoxin a day 75.4% of the patients examined (n
Drug pharmacokinetics in the obese.
Aðeins skráðir notendur geta þýtt greinar
Skráðu þig / skráðu þig
In the obese, modifications in body constitution (higher percentage of fat and lower percentage of lean tissue and water) can affect drug distribution in the tissues. For slightly liposoluble molecules (e.g., digoxin, antipyrine), the equilibrium distribution volume (V), total and per kilogram
Endogenous digitalis-like factors (EDLF) in obese individuals: preliminary results.
Aðeins skráðir notendur geta þýtt greinar
Skráðu þig / skráðu þig
We measured by RIA the serum and urinary digoxin-like immunoreactivity (EDLF) in 8 subjects with severe obesity and in 10 healthy, non-obese individuals (as a control group), to evidentiate whether circulating and urinary levels of EDLF are increased in obesity. For each individual, we measured the
Heillasta gagnagrunnur lækningajurtanna sem studdur er af vísindum
- Virkar á 55 tungumálum
- Jurtalækningar studdir af vísindum
- Jurtaviðurkenning eftir ímynd
- Gagnvirkt GPS kort - merktu jurtir á staðsetningu (kemur fljótlega)
- Lestu vísindarit sem tengjast leit þinni
- Leitaðu að lækningajurtum eftir áhrifum þeirra
- Skipuleggðu áhugamál þitt og vertu vakandi með fréttarannsóknum, klínískum rannsóknum og einkaleyfum
Sláðu inn einkenni eða sjúkdóm og lestu um jurtir sem gætu hjálpað, sláðu jurt og sjáðu sjúkdóma og einkenni sem hún er notuð við.
* Allar upplýsingar eru byggðar á birtum vísindarannsóknum
